Cipla Gulf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cipla gulf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cipla Gulf Today - Breaking & Trending Today

Cipla's Gulf arm to market, sell 4 biosimilar medicines in NZ, Australia


Cipla s Gulf arm to market, sell 4 biosimilar medicines in NZ, Australia
Cipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand, the company said in a regulatory filing
PTI | March 3, 2021 | Updated 07:47 IST
Drug major Cipla on Tuesday said its Gulf subsidiary is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand. Cipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand, the company said in a regulatory filing. ....

New Zealand , Nishant Saxena , International Business Europe Emerging , Cipla Gulf , International Business , Emerging Markets , Sumatriptan Nasal Spray , Cipla Gulf Arm , Cipla Gulf Fz Lcc , Cipla Alvotech Partnership , Cipla Biosimilar Medicines , Cipla Biosimilar Medicines In Australia , Cipla Biosimilar Medicines In New Zealand , Ceo Of Inter , புதியது ஜீலாந்து , நிஷாந்த் சகஷெண , சர்வதேச வணிக யூரோப் வளர்ந்து வருகிறது , சிப்லா வளைகுடா , சர்வதேச வணிக , வளர்ந்து வருகிறது சந்தைகள் , சிப்லா வளைகுடா கை , சிப்லா வளைகுடா ப்ஜு ல்க் , சிஇஓ ஆஃப் இடை ,

Cipla partners with Alvotech to market biosimilars in Australia and New Zealand


Cipla announced that its subsidiary, Cipla Gulf FZ LCC (Cipla Gulf) is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.
As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of
patented biosimilars of the biologic medicine brands, Aflibercept (Eylea), Ustekimumab
(Stelara), Denosumab (Prolia, Xgeva) and Golimumab (Simponi). These are leading
products covering therapeutic categories across immunology, osteoporosis, oncology
as well as ophthalmology (eg.
Aflibercept is indicated for nAMD and other serious eye
diseases).
The products are developed and manufactured by Alvotech and will be distributed by ....

New Zealand , Aflibercept Eylea , Ustekimumab Stelara , Golimumab Simponi , Cipla Gulf , Capital Market , Nifty 50 , Life Sciences , Industry Economics , Health Care , Pharmaceuticals Nec , Cipla Gulf Fz , புதியது ஜீலாந்து , சிப்லா வளைகுடா , மூலதனம் சந்தை , வாழ்க்கை அறிவியல் , தொழில் பொருளாதாரம் , ஆரோக்கியம் பராமரிப்பு , மருந்துகள் கழுத்து , சிப்லா வளைகுடா ப்ஜு ,

Cipla Gulf expands partnership with Alvotech


Cipla Gulf expands partnership with Alvotech
Premium
1 min read
. Updated: 02 Mar 2021, 10:53 AM IST PTI
Cipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand
Share Via
Read Full Story
Drug major Cipla on Tuesday said its Gulf subsidiary is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.
Cipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand, the company said in a regulatory filing. ....

New Zealand , Cipla Gulf , Biosimilar Medicines , புதியது ஜீலாந்து , சிப்லா வளைகுடா ,